Core Insights - AnaptysBio reported strong Phase 2b efficacy data for its lead program, rosnilimab, in rheumatoid arthritis, with plans to present updated data in June 2025 and initial ulcerative colitis data in Q4 2025 [2][7][8] - The company is advancing its autoimmune portfolio with multiple catalysts expected in the coming years, including ongoing Phase 1 trials for ANB033 and ANB101 [2][4][5] - AnaptysBio remains well-capitalized with a cash runway extending through the end of 2027, supported by a $75 million stock repurchase program and anticipated royalties from collaborations [2][11][12] Financial Updates - For Q1 2025, AnaptysBio reported collaboration revenue of $27.8 million, a significant increase from $7.2 million in Q1 2024, driven by royalties from Jemperli and revenue from the Vanda license agreement [11][19] - Research and development expenses rose to $41.2 million in Q1 2025 from $37.0 million in Q1 2024, primarily due to costs associated with Phase 2 trials for rosnilimab and Phase 1 trials for ANB033 and ANB101 [11][19] - The net loss for Q1 2025 was $39.3 million, or $1.28 per share, compared to a net loss of $43.9 million, or $1.64 per share, in the same period of 2024 [11][16][19] Portfolio Updates - Rosnilimab is in a Phase 2b trial for rheumatoid arthritis and a Phase 2 trial for ulcerative colitis, with positive results reported in a 424-patient Phase 2b RA trial [3][8][14] - ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator, are both in Phase 1 trials, with enrollment ongoing for healthy volunteers [4][5][7] - The company has a collaboration with GSK, which includes anticipated milestone payments and royalties from the sales of Jemperli [9][12][14]

Core Viewpoint - Vanda Pharmaceuticals Inc. has filed a New Drug Application (NDA) for Bysanti™ (milsaperidone) with the FDA, which has set a target decision date of February 21, 2026, with no review issues identified at this time [1] Group 1: Product Development - Bysanti™ is a new chemical entity identified as an active metabolite of iloperidone, showing bioequivalence to iloperidone in clinical studies at both low and high doses [2] - The efficacy and safety of Bysanti™ for bipolar I manic and mixed episodes and schizophrenia are supported by clinical studies related to iloperidone, including two studies in acute schizophrenia episodes and one in bipolar I disorder [4] - Bysanti™ is currently being studied as a once-a-day adjunctive treatment for major depressive disorder (MDD) in patients with inadequate response to current treatments, with results expected in 2026 [5] Group 2: Market Potential and Exclusivity - If approved, Bysanti™ could be available for sale in the U.S. in 2026 and is eligible for 5 years of regulatory data exclusivity [5] - Current patent applications related to Bysanti™ could extend exclusivity into the 2040s [5][8] Group 3: Mechanism of Action - Bysanti™ belongs to the class of atypical antipsychotics, interacting with various neurotransmitter receptors, including alpha-adrenergic, serotonin, and dopamine receptors, which are believed to explain its therapeutic effects [6][8] - The discovery of bioequivalence to iloperidone allows for efficient development and exploration of additional therapeutic applications for Bysanti™ [7]